Status:
UNKNOWN
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
In January 2020, researchers isolated and sequenced in China from patients with severe atypical pneumonia a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coron...
Eligibility Criteria
Inclusion
- 18 years and older
- All patients hospitalized in Amiens University Hospital with COVID-19 infection
Exclusion
- Autoimmune diseases
- Chronic viral infection by hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV)
- Immunosuppressive treatment
- Solid tumors
- Hematological malignancies
Key Trial Info
Start Date :
February 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05242159
Start Date
February 15 2022
End Date
August 1 2023
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France, 80054